Literature DB >> 8109836

Treatment of autoimmune uveitis.

S M Whitcup1, R B Nussenblatt.   

Abstract

The number of effective drugs for the treatment of autoimmune uveitis has greatly increased over the past 40 years. Many patients previously condemned to blindness can now be successfully treated with new immunosuppressive agents. New targets of the immune system, such as cell adhesion molecules, may offer novel therapeutic approaches for the treatment of inflammatory disease. However, since the catholicon for uveitis is not yet available, the search for new antiinflammatory therapy continues.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8109836     DOI: 10.1111/j.1749-6632.1993.tb17166.x

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  5 in total

Review 1.  Intravenous immunoglobulin in eye involvement.

Authors:  Zera Tellier
Journal:  Clin Rev Allergy Immunol       Date:  2005-12       Impact factor: 8.667

2.  A suppressive oligodeoxynucleotide inhibits ocular inflammation.

Authors:  C Fujimoto; D M Klinman; G Shi; H Yin; B P Vistica; J D Lovaas; E F Wawrousek; T Igarashi; C-C Chan; I Gery
Journal:  Clin Exp Immunol       Date:  2009-06       Impact factor: 4.330

3.  Green tea catechins alleviate autoimmune symptoms and visual impairment in a murine model for human chronic intraocular inflammation by inhibiting Th17-associated pro-inflammatory gene expression.

Authors:  Jian Li; Yolanda Wong Ying Yip; Jialin Ren; Wing Ki Hui; Jing Na He; Qiu Xiao Yu; Kai On Chu; Tsz Kin Ng; Sun On Chan; Chi Pui Pang; Wai Kit Chu
Journal:  Sci Rep       Date:  2019-02-19       Impact factor: 4.379

Review 4.  Anti-inflammatory Effects of GTE in Eye Diseases.

Authors:  Jian Li; Lin Du; Jing Na He; Kai On Chu; Cosmos Liutao Guo; Mandy Oi Man Wong; Chi Pui Pang; Wai Kit Chu
Journal:  Front Nutr       Date:  2021-12-13

5.  Digoxin Inhibits Induction of Experimental Autoimmune Uveitis in Mice, but Causes Severe Retinal Degeneration.

Authors:  Samuel J H Hinshaw; Osato Ogbeifun; Wambui S Wandu; Cancan Lyu; Guangpu Shi; Yichao Li; Haohua Qian; Igal Gery
Journal:  Invest Ophthalmol Vis Sci       Date:  2016-03       Impact factor: 4.799

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.